Literature DB >> 16103539

Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond.

S J Walsh1, M S Spence, D Crossman, A A J Adgey.   

Abstract

A comprehensive appraisal was undertaken on behalf of the British Cardiac Society and the Royal College of Physicians of London to assess the use of clopidogrel in acute coronary syndromes. The appraisal was submitted to the National Institute for Clinical Excellence (NICE) in August 2003 and contributed to the development of the recently published guidelines for the use of clopidogrel in acute coronary syndromes. The submission to NICE and more recent publications evaluating the use of clopidogrel are reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103539      PMCID: PMC1769101          DOI: 10.1136/hrt.2004.051722

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  41 in total

1.  Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested.

Authors:  Victor L Serebruany; Steven R Steinhubl; Charles H Hennekens
Journal:  Circulation       Date:  2003-04-01       Impact factor: 29.690

2.  Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.

Authors:  Paul A Gurbel; Charles C Cummings; Christopher R Bell; Amanda B Alford; Andrew F Meister; Victor L Serebruany
Journal:  Am Heart J       Date:  2003-02       Impact factor: 4.749

Review 3.  Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.

Authors:  Shamir R Mehta; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2003-02-19       Impact factor: 24.094

4.  Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.

Authors:  Ron J G Peters; Shamir R Mehta; Keith A A Fox; Feng Zhao; Basil S Lewis; Steven L Kopecky; Rafael Diaz; Patrick J Commerford; Vicent Valentin; Salim Yusuf
Journal:  Circulation       Date:  2003-09-22       Impact factor: 29.690

5.  Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial.

Authors:  Franz-Josef Neumann; Adnan Kastrati; Gisela Pogatsa-Murray; Julinda Mehilli; Hildegard Bollwein; Hans-Peter Bestehorn; Claus Schmitt; Melchior Seyfarth; Josef Dirschinger; Albert Schömig
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

6.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.

Authors:  Adnan Kastrati; Julinda Mehilli; Helmut Schühlen; Josef Dirschinger; Franz Dotzer; Jurriën M ten Berg; Franz-Josef Neumann; Hildegard Bollwein; Christian Volmer; Meinrad Gawaz; Peter B Berger; Albert Schömig
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

7.  Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.

Authors:  Wei C Lau; Lucy A Waskell; Paul B Watkins; Charlene J Neer; Kevin Horowitz; Amy S Hopp; Alan R Tait; David G M Carville; Kirk E Guyer; Eric R Bates
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

8.  Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.

Authors:  Jacqueline Saw; Steven R Steinhubl; Peter B Berger; Dean J Kereiakes; Victor L Serebruany; Danielle Brennan; Eric J Topol
Journal:  Circulation       Date:  2003-08-18       Impact factor: 29.690

9.  Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.

Authors:  Wei C Lau; Paul A Gurbel; Paul B Watkins; Charlene J Neer; Amy S Hopp; David G M Carville; Kirk E Guyer; Alan R Tait; Eric R Bates
Journal:  Circulation       Date:  2004-01-05       Impact factor: 29.690

10.  Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.

Authors:  Paul A Gurbel; Kevin P Bliden; Bonnie L Hiatt; Christopher M O'Connor
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

View more
  2 in total

Review 1.  Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.

Authors:  Tobias Heer; Claus Juenger; Anselm K Gitt; Timm Bauer; Frank Towae; Ralf Zahn; Jochen Senges; Uwe Zeymer
Journal:  J Thromb Thrombolysis       Date:  2008-12-20       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.